Dopamine prodrug — crosses the BBB via LAT1 (dopamine does not). Decarboxylated by AADC to dopamine both centrally and peripherally. Carbidopa (peripheral AADC inhibitor) is co-administered to prevent peripheral dopamine formation (nausea, hypotension) and preserve more L-DOPA for CNS conversion.
Half-Life & Elimination Curve (PO: 1.5h)
Plasma (PO)t½ Decay (1.5h)Effect Site (ke0)
0×t½0h100%(0.883 mg/L)
1×t½1.5h50%(0.442 mg/L)
2×t½3h25%(0.221 mg/L)
3×t½4.5h12.5%(0.11 mg/L)
4×t½6h6.3%(55.2 µg/L)
5×t½7.5h3.1%(27.6 µg/L)
Elimination t½1.5h (PO)
Rate Constant (ke)0.462 h⁻¹
Time to Peak (Tmax)1.44h
Est. Peak (Cmax)0.883 mg/L
Clearance (CL)32.3 L/h
97% Washout (5×t½)7.5h
Dosing Guidelines
Oral (PO): Typical 400 mg (Range: 100–1000 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 30% · Volume of Distribution (Vd): 70 L · Absorption (ka): 1 h⁻¹ (t½ka ≈ 42m) [PMID 4073849]